The effect of DPP-4 inhibitors on asthma control : an administrative database study to evaluate a potential pathophysiological relationship by Colice, Gene et al.
© 2017 Colice et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. 
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work 
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For 
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Pragmatic and Observational Research 2017:8 231–240
Pragmatic and Observational Research Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
231
O R I G I N A L  R E S E A R C H
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/POR.S144018
The effect of DPP-4 inhibitors on asthma control: 
an administrative database study to evaluate a 
potential pathophysiological relationship
Gene Colice1 
David Price2,3 
Maria Gerhardsson de 
Verdier4 
Karma Rabon-Stith5
Christopher Ambrose5
Katherine Cappell6
Debra E Irwin7
Paul Juneau7
Anna Vlahiotis7
In collaboration with 
Respiratory Effectiveness 
Group (REG)
1Global Medicines Development, 
AstraZeneca, Gaithersburg, MD, USA; 
2Observational & Pragmatic Research 
Institute, Singapore; 3Centre of 
Academic Primary Care, University 
of Aberdeen, Aberdeen, UK; 4Global 
Medical Affairs, AstraZeneca, Mölndal, 
Sweden; 5Global Medical Affairs, 
AstraZeneca, Gaithersburg, MD, 
USA; 6Custom Data Analytics, Life 
Sciences, Truven Health Analytics, an 
IBM Watson Health Company, Ann 
Arbor, MI, USA; 7Outcomes Research, 
Life Sciences, Truven Health Analytics, 
an IBM Watson Health Company, 
Bethesda, MD, USA
Rationale: DPP-4 may regulate immunological pathways implicated in asthma. Assessing 
whether DPP-4 inhibitor (DPP-4i) use might affect asthma control is clinically important because 
DPP-4i use in type 2 diabetes mellitus management (T2DM) is increasing. This study evaluated 
associations between DPP-4i use and asthma control.
Methods: This was a retrospective, observational, matched cohort study using administrative 
claims in the MarketScan® Commercial Claims and Encounters (Commercial) and Medicare 
Supplemental and Coordination of Benefits (Medicare Supplemental) databases. Adult asthma 
patients initiating an oral DPP-4i or a non-DPP-4i between November 1, 2006 and March 
31, 2014 were included. Patients were followed for asthma-related outcomes for 12 months 
after initiation of the antidiabetes medication. Outcomes included risk-domain asthma control 
(RDAC), defined as no asthma hospitalizations, no lower respiratory tract infections, and no 
oral corticosteroid (OCS) prescriptions; overall asthma control (RDAC criteria plus limited 
short-acting beta agonist use); treatment stability (RDAC criteria plus no increase of ≥50% in 
inhaled corticosteroid dose or addition of other asthma therapy); and severe asthma exacerbation 
rates (asthma-related hospitalizations, emergency room visits, or acute treatments with OCS). 
Comparisons were made between two matched cohorts (DPP-4i vs. non-DPP-4i initiators) using 
multivariable logistic regression and generalized linear modeling. Covariates included baseline 
demographic and clinical characteristics related to asthma and T2DM.
Results: The adjusted odds of achieving RDAC (odds ratio [OR]: 1.05; 95% CI: 0.964 to 
1.147), overall asthma control (OR: 1.04; 95% CI: 0.956 to 1.135), and treatment stability (OR: 
1.04; 95% CI: 0.949 to 1.115) did not differ between the DPP-4i and non-DPP-4i cohorts. A 
difference was not found between cohorts in severe asthma exacerbation rates during the 12 
months following initiation of antidiabetes treatment (mean = 0.32 vs. 0.34 exacerbations per 
subject-year, respectively; p=0.064). 
Conclusion: Asthma control was similar between patients initiating DPP-4i and non-DPP-4i 
antidiabetes medications, suggesting no association between DPP-4i use and asthma control. 
Keywords: asthma control, DPP-4i, type 2 diabetes
Introduction
CD26 is a membrane-anchored ectoenzyme with DPP-4 activity.1–4 CD26 is found on 
T lymphocytes (more often on CD4+ than CD8+ lymphocytes), widely distributed 
 throughout the body, in high concentrations in lung connective tissue and in lower 
 concentrations in the apical membrane of bronchial epithelial cells and submucosal glands. 
DPP-4 is the circulating form of CD26 and is found in blood and biologic fluids, such 
as bronchoalveolar lavage. DPP-4 is the major member of the S9B subfamily of serine 
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 proteases, which cleave N-terminal dipeptides from proteins 
with a penultimate proline or alanine. DPP-4 plays an important 
role in glucose homeostasis by inactivating  incretins. Incretin 
hormones increase glucose-dependent  secretion of insulin, 
which reduces post-prandial plasma glucose. In patients with 
type 2 diabetes mellitus (T2DM), therapeutic inhibition of 
DPP-4 reduces proteolysis and increases intact post-prandial 
incretin levels, thereby decreasing blood glucose.5
DPP-4 activity may regulate immunological pathways 
implicated in asthma by interacting with key mediators and 
by inactivating chemokines.1 In vitro DPP-4 cleaves eotaxin 
and down-regulates its eosinophilic chemotactic potency.6,7 In 
a rat asthma model, DPP-4 inactivated eotaxin and reduced 
eosinophil chemotaxis.7 In this model, DPP-4 deficient rats 
had enhanced eosinophil chemotaxis. DPP-4 also inhibits 
 chemotaxis by inactivating RANTES.8 A study in CD26 knock-
out mice showed enhanced airway  inflammation and increased 
levels of eotaxin and RANTES with ovalbumin sensitization.9 
Other research, though, showed that DPP-4 inhibition led 
to reduced airway inflammation.10  Immunohistochemistry 
 techniques showed DPP-4 staining in airway biopsies of 
asthma patients. Shiobura et al found greater expression of 
DPP-4 in bronchial epithelial cells,11 but van der Velden et al 
did not  confirm this finding in a similar study.12 Elevated 
membrane DPP-4 expression has been observed on T cells 
in asthma patients.13 A role for DPP-4 in inflammatory 
 respiratory diseases such as asthma has thus been suggested by 
 Giovannini-Chami et al14 who found elevated DPP-4 transcripts 
in the nasal epithelia of children with dust mite allergic rhinitis, 
which is known to be associated with uncontrolled asthma. 
From these varied observations it is unclear if DPP-4 activity 
plays a role in either up- or down-regulating key aspects in 
asthma pathophysiology.
The potential role of DPP-4 in asthma pathophysiology is 
a clinically important issue because of the increasing use of 
DPP-4 inhibitors (DPP-4is) to manage T2DM patients, some of 
whom may have concomitant asthma. To test the hypothesis that 
DPP-4i use affects asthma control, this study compared asthma 
outcomes between asthma patients newly initiating treatment 
with DPP-4i vs. other antidiabetic medications over a 1-year 
follow-up period using well-established administrative database 
methods.15–18 The hypothesis tested in this study was identified 
a priori with a commitment to publish the findings of the study. 
Materials and methods
Data sources
This was a retrospective, observational, matched cohort 
study based on US administrative claims data extracted 
from the MarketScan® Commercial Claims and Encounters 
 (Commercial) and Medicare Supplemental and  Coordination 
of Benefits (Medicare Supplemental) databases. These 
 databases contain enrollment information, demographic 
information, and inpatient medical, outpatient medical, and 
outpatient pharmacy claims data. The Commercial database 
includes information for individuals under the age of 65 years 
who are the primary insured or a spouse or dependent thereof. 
The Medicare Supplemental database includes information 
for individuals who are Medicare-eligible (primarily those 
over the age of 65 years) and have supplemental insurance 
paid for by their current or former employer. The Medicare 
Supplemental database includes both the Medicare-paid and 
supplemental-paid components of reimbursed  administrative 
claims. As described in greater detail in the following 
 section, study data were collected from the database using 
 enrollment records, International Classification of Diseases, 
9th  Revision, Clinical Modification (ICD-9-CM) codes, 
 Current Procedural Technology 4th edition codes, Healthcare 
Common Procedure Coding System codes, and National 
Drug Codes, as appropriate. All study data were accessed 
with protocols compliant with US patient confidentiality 
requirements, including the Health Insurance Portability and 
Accountability Act of 1996 (HIPAA) regulations. As this 
study used only de-identified patient records, it was exempted 
from Institutional Review Board approval.
Inclusion/exclusion criteria
The pre-specified study population comprised adult asthma 
patients with comorbid T2DM who were newly  initiating 
either an oral DPP-4i or a non-DPP-4i  antidiabetes 
 medication. Patients were included in the study if they had 
at least one outpatient pharmacy claim for a DPP-4i or 
another non-DPP-4i antidiabetic medication not including 
metformin or insulin between November 1, 2006 and March 
31, 2014. The date of the first of such pharmacy claims for 
a DPP-4i or non-DPP-4i was designated as the index date; 
the identity of the medication class on this claim determined 
the index medication class. Patients were also required to be 
at least 18 years old on the index date, have at least 1 year 
of continuous enrollment in medical and pharmacy benefits 
prior to the index date (designated the baseline period), and 
have at least 1 year of continuous enrollment in medical 
and pharmacy benefits after the index date (designated the 
follow-up period). 
Included patients were also required to have evidence 
of an asthma diagnosis as indicated by meeting at least one 
of the following criteria in the baseline period or on the 
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index date: 1) at least one inpatient claim or one emergency 
department (ED) claim with a primary diagnosis for asthma 
(ICD-9-CM code 493.0x, 493.1x, or 493.9x) as specified 
in the Healthcare Effectiveness Data and Information Set 
(HEDIS) claims-based definition for persistent asthma.19 
Given the potential for misclassification using the HEDIS 
criteria, asthma was also identified in patients with; 2) two 
or more other (i.e., non-ED) outpatient medical claims with 
an asthma diagnosis or; 3) at least one inpatient or outpatient 
medical claim with an asthma diagnosis along with at least 
one outpatient prescription claim for an asthma  medication, 
including immunomodulators, inhaled corticosteroids 
(ICS), long-acting beta agonists (LABAs), ICS/LABA 
 combinations, leukotriene modulators, mast cell stabilizers, 
short-acting beta agonists (SABAs), or xanthines. 
Two mutually exclusive study cohorts were defined from 
the study population. All patients fell into one of the two 
following cohorts: the DPP-4i cohort comprised patients 
who newly initiated alogliptin, linagliptin, saxagliptin, 
sitagliptin, or combination products (e.g., pioglitazone/ 
sitagliptin) on the index date; the non-DPP-4i cohort 
 comprised patients who newly initiated an alpha-glucosidase 
inhibitor, amylin analog, glucagon-like peptide-1  receptor 
agonist, meglitinide, sodium-glucose co-transporter 2 
inhibitor, sulfonylurea, and/or thiazolidinedione on the 
index date. Metformin was not included as a non-DPP-4i 
index medication because of the widespread prevalence of 
use of metformin as first-line antidiabetes therapy.20 Follow-
up after the initial exposure (index date) was conducted in 
an intention-to-treat manner. 
Patients in either cohort were excluded from the study if 
they had an outpatient prescription drug claim for a DPP-4i 
during the baseline period. Patients in the non-DPP-4i cohort 
were excluded if they had any outpatient prescription drug 
claims for any medication in the same non-DPP-4i  medication 
class as their index prescription during the baseline period. 
Patients in both groups were excluded if they had a medical 
claim with an ICD-9-CM diagnosis code indicative of COPD 
or chronic respiratory tract disease other than asthma during 
the baseline or follow-up periods.
Study variables
The primary independent variable was a dichotomous 
 indicator for membership in the DPP-4i or non-DPP-4i 
cohort. Baseline measures of patient demographics,  general 
health status, asthma and diabetes severity, comorbid 
 conditions, along with asthma and diabetes medication 
utilization were also collected.
Study outcomes were risk-domain asthma control 
(RDAC), overall asthma control, treatment stability, and 
 number of severe asthma exacerbations, which were 
 rospectively defined as follows:18 
•	 RDAC during the 12-month period following the index 
date (yes/no): a composite measure based on a patient 
having no recorded asthma-related hospital attendance, 
including inpatient admission, ED attendance, or  outpatient 
hospital attendance; no outpatient  consultation for lower 
respiratory tract infection (LRTI) with a  resultant antibiotic 
prescription; and no outpatient prescriptions for an acute 
course of oral corticosteroids (OCS) during the follow-up 
period. Asthma-related hospitalization was considered as 
any admission or ED attendance with an ICD-9-CM diag-
nosis indicative of either asthma or LRTI in any diagnosis 
 position. An acute course of OCS was specifically defined 
as a prescription with days supplied less than or equal to 14 
days or with days supplied greater than 14 days and daily 
dosage greater than 10 mg. LRTI requiring antibiotics were 
infections for which an antibiotic was prescribed on the 
same day as the recorded diagnosis. 
•	 Overall asthma control during the 12-month period 
 following the index date (yes/no): a composite measure 
comprising the three previously mentioned criteria for 
RDAC, plus limited SABA use (average daily dose of 
≤180 μg albuterol equivalents) as a fourth criterion. 
•	 Treatment stability during the 12-month period following 
the index date (yes/no): a composite measure  comprising 
the three previously mentioned criteria for RDAC, plus 
no asthma treatment change as a fourth criterion. Asthma 
treatment change was specifically defined as either 
increased ICS dose (average daily dose increased by greater 
than or equal to 50% from the baseline period to the follow-
up period) or use of additional asthma therapy, such as a 
LABA, leukotriene receptor antagonist, or theophylline. 
•	 Severe asthma exacerbations during the 12-month period 
following the index date were defined as either an asthma-
related hospital admission, ED attendance, or an acute 
outpatient course of OCS. Any such events within a 2-week 
window were counted as a single exacerbation. For asthma-
related hospitalizations and ED attendance, diagnoses of 
asthma were permitted to appear in any diagnosis position.
Statistical analysis
Patients in the DPP-4i cohort were directly matched to those 
in the non-DPP-4i cohort on demographic and baseline 
covariates that were hypothesized to possibly affect study 
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outcomes, with the exception of patient age, which was 
matched using an age range. Patients were considered a 
suitable match if their respective ages were within 5 years of 
one another. Other factors matched directly were sex, baseline 
number of acute OCS prescriptions, baseline SABA daily 
dose, baseline ICS daily dose, and baseline adapted Diabetes 
Complication Severity Index (aDCSI)21 score. DPP-4i 
patients were matched to non-DPP-4i patients at a 1:2 ratio, 
with 1:1 matched pairs substituted where 1:2 matching was 
not possible. Patients were matched before outcomes were 
examined. The analysis was conducted on an intention-to-treat 
basis in that patients who were classified into the non-DPP-4i 
cohort based on new initiation of a non-DPP-4i medication at 
index, but who subsequently filled a prescription for a DPP-4i 
after the index date, were not excluded. 
RDAC, overall asthma control, and treatment stability 
during the follow-up period were compared between the 
matched DPP-4i and non-DPP-4i cohorts, treating the non-
DPP-4i cohort as the reference category, with individual 
standard logistic regression models with a unique outcome as 
a dependent variable, controlling for other covariates. Odds 
ratios (ORs) from logistic regression models, along with 
their 95% CIs, were computed for the pre-specified binary 
outcomes. The rate of severe asthma exacerbations during 
the follow-up period was compared between the matched 
DPP-4i and non-DPP-4i cohorts, treating the non-DPP-4i 
cohort as the reference category, through a generalized linear 
regression model, assuming an underlying negative binomial 
distribution. Covariates included in the logistic and negative 
binomial regression models were demographic characteristics 
not used for direct matching, diabetes- and asthma-related 
comorbidities, all diabetes- and asthma-related medication 
history measures not used for direct matching, and the Deyo-
Charlson Comorbidity Index (DCI).22 No offset was used for 
the negative binomial model, as all patients were followed for 
a fixed 1-year follow-up period. For all outcomes, a p-value 
of p<0.05 was used to denote statistical significance.
Results
A total of 4,304 patients met all of the criteria for inclusion 
in the DPP-4i cohort, and 12,659 patients met criteria for 
inclusion in the non-DPP-4i cohort. There were 916 (7.2%) 
non-DPP-4i patients who filled at least one prescription for 
a DPP-4i after the index date. After matching, 3,973 patients 
remained in the DPP-4i cohort and 7,487 patients remained 
in the non-DPP-4i cohort (n=3,514 1:2 match ratio; n=459 
1:1 match ratio). Baseline demographic characteristics were 
similar between the groups (Table 1). Mean age was 53.7 
years for the DPP-4i cohort and 53.4 years for the non-DPP-4i 
cohort. Approximately 70% of the patients were females in 
each of the matched cohorts. Although there were significant 
differences between the two cohorts with regards to some 
baseline patient characteristics (health insurance plan type, 
geographic region, and index year), these differences were 
considered small and not clinically meaningful.
The DPP-4i cohort had significantly higher mean DCI 
scores (2.22 vs. 2.11, p<0.05) and mean aDCSI scores (0.53 
vs. 0.49, p<0.05) at baseline compared with the non-DPP-4i 
Table 1 Patient characteristics
Characteristic DPP-4i
N=3,973
Non-DPP-4i
N=7,487
p-value
Age (Mean, SD)1 53.7 (10.5) 53.4 (10.3) 0.150
Sex (N, %)1 0.563
Male 1,244 (31.3%) 2,305 (30.8%)
Female 2,729 (68.7%) 5,182 (69.2%)
Health insurance plan 
type (N, %)
<0.001
Comprehensive 304 (7.7%) 551 (7.4%)
EPO 50 (1.3%) 81 (1.1%)
HMO 514 (12.9%) 1,374 (18.4%)
POS 320 (8.1%) 571 (7.6%)
PPO 2,410 (60.7%) 4,308 (57.5%)
POS with capitation 25 (0.6%) 32 (0.4%)
CDHP 161 (4.1%) 210 (2.8%)
HDHP 48 (1.2%) 76 (1.0%)
Other/unknown 141 (3.5%) 284 (3.8%)
Payer (N, %) 0.414
Commercial 3,487 (87.8%) 6,610 (88.3%)
Medicare 486 (12.2%) 877 (11.7%)
Geographic region (N, %) <0.001
Northeast 871 (21.9%) 1,172 (15.7%)
North Central 857 (21.6%) 1,786 (23.9%)
South 1,604 (40.4%) 2,950 (39.4%)
West 604 (15.2%) 1,509 (20.2%)
Unknown 37 (0.9%) 70 (0.9%)
Population density (N, %) 0.502
Urban 3,384 (85.2%) 6,320 (84.4%)
Rural 554 (13.9%) 1,104 (14.7%)
Unknown 35 (0.9%) 63 (0.8%)
Index year (N, %) <0.001
2006 38 (1.0%) 215 (2.9%)
2007 374 (9.4%) 1,067 (14.3%)
2008 410 (10.3%) 916 (12.2%)
2009 405 (10.2%) 1,051 (14.0%)
2010 562 (14.1%) 1,203 (16.1%)
2011 745 (18.8%) 1,119 (14.9%)
2012 686 (17.3%) 926 (12.4%)
2013 623 (15.7%) 792 (10.6%)
2014 130 (3.3%) 198 (2.6%)
Notes: 1Used in direct matching. The bold value denotes statistical significance 
(p<0.05).
Abbreviations: CDHP, consumer-driven health plan; DPP-4i, DPP-4 inhibitor; 
EPO, exclusive provider organization;  HDHP, high deductible health plan; HMO, 
health maintenance organization; POS, point-of-service; PPO, preferred provider 
organization.
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cohort (Table 2). A significantly higher proportion of patients 
(p<0.05) in the DPP-4i cohort had rhinitis and eczema than 
in the non-DPP-4i cohort. Patients in the DPP-4i cohort 
also had significantly higher observed rates of hypertension, 
dyslipidemia, atherosclerosis, and peripheral vascular disease 
compared to the non-DPP-4i cohort (all p<0.05).
Asthma medication use during the baseline period was 
similar for the two cohorts (Table 3). Approximately 64% of 
patients received no OCS treatment, 23% received a single 
course, and 6% received three or more courses. During the 
baseline period, approximately 45% of patients in each cohort 
received no treatment with SABA and approximately 55% 
in each cohort received no treatment with ICS. There was a 
significant difference between the two cohorts in utilization 
of controller medications, but the difference was small and 
not clinically relevant. A significantly greater proportion of 
DPP-4i than non-DPP-4i initiators received metformin  during 
the baseline period (58.8% vs. 52.8%, p<0.05), but there was 
no statistically significant difference between cohorts for the 
proportion of patients with prior exposure to insulins.
In the baseline period, there were no significant differences 
between the two cohorts in RDAC, overall asthma control, 
and number of severe asthma exacerbations (Table 4). There 
were significant differences in two components of the RDAC 
relating to inpatient admissions, ED visits, and outpatient 
hospital visits for asthma and LRTI, but these differences 
were small. 
During the 1-year follow-up period, all aspects of asthma 
control improved compared to baseline in both cohorts, but 
RDAC, overall asthma control, and number of severe asthma 
exacerbations were similar for the DPP-4i and non-DPP-4i 
cohorts (Table 5). Again seen were significant differences 
between the two cohorts in components of the RDAC. Post-
period treatment stability (which was not measured during the 
baseline period) was also comparable between the DPP-4i and 
non-DPP-4i cohorts. Multivariable logistic regression analysis 
Table 2 Baseline health status and comorbid conditions
Clinical characteristic DPP-4i
N=3,973
Non-DPP-4i
N=7,487
p-value
General health status
Deyo-Charlson Comorbidity Index (Mean, SD) 2.22 (1.2) 2.11 (1.1) <0.0001
Adapted Diabetes Complication Score Index (Mean, SD)1 0.53 (1.0) 0.49 (0.9) 0.015
Comorbid conditions
Hypertension 2,700 (68.0%) 4,927 (65.8%) 0.020
Dyslipidemia 2,443 (61.5%) 4,215 (56.3%) <0.0001
Rhinitis 1,091 (27.5%) 1,801 (24.1%) <0.0001
Gastroesophageal reflux disease 540 (13.6%) 925 (12.4%) 0.059
Atherosclerosis 380 (9.6%) 633 (8.5%) 0.046
Ischemic heart disease 349 (8.8%) 633 (8.5%) 0.549
Eczema 348 (8.8%) 567 (7.6%) 0.026
Depression 344 (8.7%) 729 (9.7%) 0.059
Anxiety 284 (7.1%) 522 (7.0%) 0.726
Diabetic peripheral neuropathy 178 (4.5%) 323 (4.3%) 0.679
Diabetic retinopathy 168 (4.2%) 320 (4.3%) 0.909
Smoking2 105 (2.6%) 223 (3.0%) 0.305
Heart failure 98 (2.5%) 171 (2.3%) 0.539
Peripheral vascular disease 87 (2.2%) 121 (1.6%) 0.029
Renal impairment 75 (1.9%) 143 (1.9%) 0.934
Obesity 54 (1.4%) 96 (1.3%) 0.730
Diabetic nephropathy 52 (1.3%) 130 (1.7%) 0.082
Stroke 48 (1.2%) 63 (0.8%) 0.057
Psoriasis 46 (1.2%) 87 (1.2%) 0.984
Unstable angina pectoris 35 (0.9%) 81 (1.1%) 0.307
Pulmonary hypertension 25 (0.6%) 41 (0.5%) 0.583
Percutaneous coronary intervention 18 (0.5%) 39 (0.5%) 0.623
Anaphylaxis 16 (0.4%) 39 (0.5%) 0.384
Myocardial infarction 15 (0.4%) 43 (0.6%) 0.158
Coronary artery bypass graft 6 (0.2%) 13 (0.2%) 0.777
Notes: 1Used in direct matching; 2claims-based history of tobacco use/tobacco dependence. The bold value denotes statistical significance (p<0.05).
Abbreviation: DPP-4i, DPP-4 inhibitor.
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Table 3 Baseline medication utilization
Medication utilization DPP-4i
N=3,973
Non-DPP-4i
N=7,487
p-value
Asthma-related medications
Number of acute oral corticosteroid courses1 (N, %) 0.324
0 2,507 (63.1%) 4,834 (64.6%)
1 942 (23.7%) 1,737 (23.2%)
2 287 (7.2%) 518 (6.9%)
≥3 237 (6.0%) 398 (5.3%)
Mean SABA daily dose, albuterol 
equivalents1 (N, %)
0.833
0 µg 1,751 (44.1%) 3,340 (44.6%)
1–100 µg 1,566 (39.4%) 2,981 (39.8%)
101–200 µg 284 (7.1%) 502 (6.7%)
201–300 µg 172 (4.3%) 318 (4.2%)
301–400 µg 46 (1.2%) 75 (1.0%)
>400 µg 154 (3.9%) 271 (3.6%)
Mean ICS daily dose, fluticasone propionate equivalents1 (N, %) 0.166
0 µg 2,201 (55.4%) 4,210 (56.2%)
1–199 µg 1,562 (39.3%) 2,951 (39.4%)
200–399 µg 169 (4.3%) 276 (3.7%)
400–599 µg 38 (1.0%) 46 (0.6%)
600–799 µg 1 (0.0%) 1 (0.0%)
≥800 µg 2 (0.1%) 3 (0.0%)
Number of asthma prescriptions, control medications (N, %) <0.0001
0 1,639 (41.3%) 3,238 (43.2%)
1 630 (15.9%) 1,310 (17.5%)
2 317 (8.0%) 713 (9.5%)
3 299 (7.5%) 470 (6.3%)
4 274 (6.9%) 410 (5.5%)
≥5 814 (20.5%) 1,346 (18.0%)
Number of asthma prescriptions, rescue 
medications (N, %)
0.130
0 1,685 (42.4%) 3,163 (42.2%)
1 1,241 (31.2%) 2,447 (32.7%)
2 502 (12.6%) 954 (12.7%)
≥3 545 (13.7%) 923 (12.3%)
Number of antibiotic courses for LRTI (N, %) 0.702
0 3,727 (93.8%) 7,061 (94.3%)
1 224 (5.6%) 387 (5.2%)
2 17 (0.4%) 28 (0.4%)
≥3 5 (0.1%) 11 (0.1%)
Acetaminophen (N, %) 1,454 (36.6%) 2,882 (38.5%) 0.046
Non-steroidal anti-inflammatory drugs (N, %) 1,168 (29.4%) 2,162 (28.9%) 0.558
Beta-blockers (N, %) 822 (20.7%) 1,609 (21.5%) 0.318
Diabetes medications (N, %)
Alpha-glucosidase inhibitors 0 (0%) 2 (0%) 0.547
Amylin analogs 1 (0%) 1 (0%) 1.000
Biguanides (metformin) 2,337 (58.8%) 3,952 (52.8%) <0.0001
Glucagon-like peptide-1 receptor agonists 12 (0.3%) 8 (0.1%) 0.017
Insulins2 312 (7.9%) 647 (8.6%) 0.147
Short-acting 154 (3.9%) 348 (4.6%) 0.055
Long-acting 254 (6.4%) 502 (6.7%) 0.522
Combination 53 (1.3%) 120 (1.6%) 0.261
Meglitinides and combinations 3 (0.1%) 4 (0.1%) 0.700
Sodium-glucose co-transporter 2 inhibitors 
 and combinations 0 (0%) 0 (0%) n/a
Sulfonylureas and combinations 25 (0.6%) 63 (0.8%) 0.216
Thiazolidinediones and combinations 36 (0.9%) 57 (0.8%) 0.411
Notes: 1Used in direct matching; 2percent of patients using different insulin types is not mutually exclusive. The bold value denotes statistical significance (p<0.05).
Abbreviations: DPP-4i, DPP-4 inhibitor; ICS, inhaled corticosteroids; LRTI, lower respiratory tract infection; n/a, not applicable; SABA, short-acting beta agonist.
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revealed no significant difference between the DPP-4i cohort 
and non-DPP-4i cohort in odds of achieving RDAC (OR =1.05, 
95% CI =0.96–1.15), overall asthma control (OR =1.04, 95% 
CI =0.96–1.14), and treatment stability (OR =1.03, 95% CI 
Table 4 Baseline asthma control
Clinical characteristic
 
DPP-4i
N=3,973
Non-DPP-4i
N=7,487
p-value
Risk-domain asthma control (N, %)
Patients with no inpatient admission, emergency department, or outpatient hospital visit 
for asthma
3,133 (78.9%) 5,728 (76.5%) 0.004
Patients with no inpatient admission, emergency department, or outpatient hospital visit 
for LRTI
3,816 (96.0%) 7,074 (94.5%) <0.001
Patients with no outpatient consultation for LRTI with a resultant antibiotic prescription 3,748 (94.3%) 7,119 (95.1%) 0.085
Patients with no prescriptions for an acute course of oral corticosteroids 2,507 (63.1%) 4,834 (64.6%) 0.120
Patients meeting all of the above criteria indicating risk-domain asthma control 1,943 (48.9%) 3,655 (48.8%) 0.929
Overall asthma control (N, %)
Patients with risk-domain asthma control and limited SABA use (daily dose ≤180 µg 
albuterol equivalents)
1,781 (44.8%) 3,353 (44.8%) 0.965
Number of severe asthma exacerbations (N, %) 0.146
0 2,264 (57.0%) 4,303 (57.5%)
1 1,162 (29.2%) 2,198 (29.4%)
2 320 (8.1%) 631 (8.4%)
≥3 227 (5.7%) 355 (4.7%)
Number of asthma consultations without acute oral corticosteroids (N, %)1 0.007
0 1,093 (27.5%) 2,174 (29.0%)
1 1,727 (43.5%) 3,345 (44.7%)
2 662 (16.7%) 1,182 (15.8%)
≥3 491 (12.4%) 786 (10.5%)
Notes: 1Used in direct matching. The bold value denotes statistical significance (p<0.05).
Abbreviations: DPP-4i, DPP-4 inhibitor; LRTI, lower respiratory tract infection; SABA, short-acting beta agonist.
Table 5 Follow-up asthma control
Clinical characteristic
 
DPP-4i
N=3,973
Non-DPP-4i
N=7,487
p-value
Risk-domain asthma control (N, %)
Patients with no inpatient admission, emergency department, or outpatient hospital 
visit for asthma
3,629 (91.3%) 6,717 (89.7%) 0.005
Patients with no inpatient admission, emergency department, or outpatient hospital 
visit for LRTI
3,884 (97.8%) 7,266 (97.0%) 0.025
Patients with no outpatient consultation for LRTI with a resultant antibiotic 
prescription
3,793 (95.5%) 7,173 (95.8%) 0.398
Patients with no prescriptions for an acute course of oral corticosteroids 2,917 (73.4%) 5,538 (74.0%) 0.526
Patients meeting all of the above criteria indicating risk-domain asthma control 2,607 (65.6%) 4,894 (65.4%) 0.788
Overall asthma control (N, %)
Patients with risk-domain asthma control and limited SABA use (daily dose ≤180 µg 
albuterol equivalents)
2,404 (60.5%) 4,533 (60.5%) 0.970
Treatment stability
Patients with risk-domain asthma control and no asthma medication treatment 
change
2,108 (49.0%) 6.098 (48.2%) 0.360
Number of severe asthma exacerbations (N, %) 0.951
0 2,823 (71.1%) 5,314 (71.0%)
1 757 (19.1%) 1,420 (19.0%)
2 235 (5.9%) 462 (6.2%)
≥3 158 (4.0%) 291 (3.9%)
Note: The bold value denotes statistical significance (p<0.05).
Abbreviations: DPP-4i, DPP-4 inhibitor; LRTI, lower respiratory tract infection; SABA, short-acting beta agonist. 
=0.95–1.12) (Figure 1). The adjusted mean rate of severe 
asthma exacerbations was not significantly higher in the 
DPP-4i cohort than in the non-DPP-4i cohort (0.32 vs. 0.34 
exacerbations per subject-year; p=0.064) (Figure 2). 
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Discussion
Using well-established observational database research 
methods, this study measured, by proxy, the potential role of 
DDP-4 inhibition in the regulation of asthma immunology. 
Across several measures of asthma control, asthma outcomes 
for patients newly initiating a DPP-4i for the treatment of 
T2DM were similar to patients newly initiating non-DPP-4i 
antidiabetes medications suggesting no association between 
DPP-4i use and asthma control. 
In vitro and animal studies have suggested a possible 
role for DPP-4 in mediating key aspects of allergic airway 
inflammation.1 However, we are not aware of clinical trials 
which have addressed the clinically relevant hypothesis that 
treatment with DPP-4i might affect asthma control. This 
analysis captured the experience of patients with both asthma 
and T2DM outside the limits of a clinical trial environment by 
utilizing real world data. Using established methods15–18 we 
identified a large number of asthma patients with a wide range 
of asthma severity, from patients with relatively mild disease 
not requiring regular controller medications to patients with 
more severe asthma and frequent exacerbations, who were 
also being treated for T2DM. Asthma patients have more 
comorbidities, like T2DM, than do non-asthma patients.23 
However, clinical trials in asthma, particularly those designed 
to test new medications, may exclude significant proportions 
of the patient population potentially eligible for treatment 
with comorbidities like T2DM.24 
Access to administrative databases allowed insights into 
multiple aspects of asthma care, including prescription drug 
usage, comorbid conditions, and health care utilization. The 
endpoints used in this analysis to assess asthma control, the 
RDAC, overall asthma control, treatment stability, and number 
of severe asthma exacerbations, have been well standardized 
in previous work15–18 and are clinically relevant. Although 
administrative databases do not provide access to information 
about asthma symptoms, SABA use has been used as a 
surrogate measure of this component of asthma outcomes. An 
interesting and unexplained observation in this study is that 
measures of asthma control improved in both cohorts from the 
baseline period to the 1-year observational period. A previous 
observational database study has suggested that diabetes is a 
predictor of future asthma exacerbations.25 Whether improved 
T2DM control might also improve asthma control has not been 
evaluated in this analysis, and warrants future study. 
Other inherent strengths and weaknesses of administrative 
database analyses should be considered. The study databases 
used in this analysis comprise a wide variety of health plan 
types and formularies and the study period encompassed the 
Figure 1 Adjusted odds of risk-domain asthma control, overall asthma control, and 
treatment stability during follow-up.
Note: Models adjusted for health plan type, payer, geographic region, population 
density, index year, anaphylaxis, anxiety, depression, eczema, gastroesophageal 
reflux disease, ischemic heart disease, obesity, psoriasis, pulmonary hypertension, 
rhinitis, smoking, dyslipidemia, hypertension, renal impairment, baseline type 2 
diabetes, number of asthma control medication prescriptions, number of asthma 
rescue medication prescriptions, number of antibiotic courses to treat LRTI, 
acetaminophen utilization, NSAID utilization, beta blocker utilization, microvascular 
complications of diabetes, macrovascular complications of diabetes, baseline 
biguanide utilization, baseline insulin utilization, baseline utilization of other 
antihyperglycemic medications, baseline DCI, baseline risk-domain asthma control, 
baseline overall asthma control, baseline number of severe asthma exacerbations 
and number of asthma consultations with acute OCS prescriptions.
Abbreviations: DCI, Deyo-Charlson Comorbidity Index; LRTI, lower respiratory 
tract infection; NSAID, non-steroidal anti-inflammatory drugs; OCS, oral 
corticosteroid; OR, odds ratio.
0.50 1.51
OR
Overall asthma control
Treatment stability
Risk-domain asthma control
Figure 2 Adjusted mean estimate rate of severe asthma exacerbations during 
follow-up.
Note: Models adjusted for health plan type, payer, geographic region, population 
density, index year, anaphylaxis, anxiety, depression, eczema, gastroesophageal 
reflux disease, ischemic heart disease, obesity, psoriasis, pulmonary hypertension, 
rhinitis, smoking, dyslipidemia, hypertension, renal impairment, baseline type 2 
diabetes, number of asthma control medication prescriptions, number of asthma 
rescue medication prescriptions, number of antibiotic courses to treat LRTI, 
acetaminophen utilization, NSAID utilization, beta blocker utilization, microvascular 
complications of diabetes, macrovascular complications of diabetes, baseline 
biguanide utilization, baseline insulin utilization, baseline utilization of other 
antihyperglycemic medications, baseline DCI, baseline risk-domain asthma control, 
baseline overall asthma control, baseline number of severe asthma exacerbations 
and number of asthma consultations with acute OCS prescriptions.
Abbreviations: DCI, Deyo-Charlson Comorbidity Index; DPP-4i, DPP-4 inhibitor; 
LRTI, lower respiratory tract infection; NSAID, non-steroidal anti-inflammatory 
drugs;  OCS, oral corticosteroid.
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launch date of the first available DPP-4i. This ensured that the 
results were more generalizable than single payer databases 
or shorter time periods, which might be subject to systematic 
prescribing biases related to specific DPP-4i agents. The new-
user cohort design, with the index date through the end of the 
follow-up period clearly anchored to medication exposure, 
is the default methodology recommended by the Agency 
for Healthcare Quality and Research for observational 
comparative effectiveness research.26 In terms of design, this 
study was limited to only those individuals with commercial 
health coverage or private Medicare supplemental coverage. 
Consequently, results of this analysis may not be generalizable 
to patients with other insurance or without health insurance 
coverage, and may differ from what would be observed 
in patients outside of the US. The MarketScan Research 
Databases rely on administrative claims data for clinical 
detail. These data are subjected to data coding limitations 
and data entry error. In addition, inaccuracy in diagnoses 
and measurement of treatment exposure in claims databases 
may introduce a dilution of associations. 
The current analysis does not address the separate issue of 
whether serum DPP-4 levels may be a relevant biomarker for 
predicting response to asthma therapeutics targeting IL-13. 
IL-13 has been implicated as a central mediator of asthma 
pathophysiology, driving airway inflammation, remodeling, 
and hyper-responsiveness. In vitro experiments have shown 
that IL-13 induces DPP-4 expression in airway epithelial 
cells, suggesting that DPP-4 serum levels might identify 
asthma patients who have an enhanced benefit to anti-IL-13 
therapy. A clinical trial has shown that increased serum 
DPP-4 levels predicted a beneficial response to tralokinumab, 
an anti-IL-13 monoclonal antibody, in terms of reducing 
exacerbations, improving lung function, and alleviating 
symptoms.27 It is also important to note that the DPP-4i agents 
under study did not include inhaled formulations, and the 
study did not directly measure the impact of local pulmonary 
exposure to DPP-4is. The pharmacokinetics of pulmonary 
exposure rather than oral systemic exposure may produce 
different results, and also warrants future study.
In summary, asthma patients newly initiating a DPP-4i 
for the treatment of T2DM do not differ with respect to the 
probability of achieving asthma control as compared to 
similar patients newly initiating non-DPP-4i antidiabetes 
medications.
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